Table 1 Patient demographics and baseline disease characteristics

Age, mean years ± SD

   Patients < 50 years of age, n (%)

ECOG performance status, n (%)

   0 – 1

   2 – 3

Estrogen- and progesterone-receptor status, n (%)

   Positive for at least 1

   Other

Sites of metastasis, patients, n (%)

   Bone, any

   Bone as only metastatic site

   Lung

   Liver

   Brain

   Other

Time from primary to bone metastases diagnosis, median years ± SD

Time from bone metastases to study entry, mean years ± SD

Patients with bone lesions ≥ 1 cm in diameter, n (%)

   1 lesion

   2 lesions

   ≥ 3 lesions

Lesion types and numbers

   1 – 2 osteolytic

   ≥ 3 osteolytic

   0 osteoblastic

   1 – 2 osteoblastic

   ≥ 3 osteoblastic

   0 mixed lesions

1 – 2 mixed lesions

≥ 3 mixed lesions

Patients with SREs during the 3 months before study entry, n (%)

   Palliative radiotherapy

   Fracture

Pain scores, n (%)

   0

   1 – 3

   4 – 9

Prior therapy regimens, n (%)

   0 – 1 chemotherapy

   2 – 3 chemotherapy

   ≥ 4 chemotherapy

   0 – 1 hormonal therapy

   2 – 3 hormonal therapy

   ≥ 4 hormonal therapy